ArticleACS applied materials & interfaces2019
A New Formyl Peptide Receptor-1 Antagonist Conjugated Fullerene Nanoparticle for Targeted Treatment of Degenerative Disc Diseases.
Article in ACS applied materials & interfaces, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- FPR1 drives sepsis-associated cognitive impairment through region-specific transcriptional and splicing dysregulation in the brain.Metabolic brain disease · 2026Article
- One-Stone-Three-Birds Biomimetic Oral Targeting Delivery Strategy for On-Demand Controlled Drug Release and Intervertebral Disc Degeneration Therapy.Exploration (Beijing, China) · 2026Article
- Applications of fullerenes in the treatment of osteoarthritis.Nanomedicine (London, England) · 2026Review
- CX3CR1 modulates acute disc herniation-induced pain via regulating local inflammation and spinal microglia activation.Osteoarthritis and cartilage · 2025Article
- Understanding the Microenvironment of Intervertebral Disc Degeneration: A Comprehensive Review of Pathophysiological Insights and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials.The journal of headache and pain · 2025Review
- The anti-oxidation related bioactive materials for intervertebral disc degeneration regeneration and repair.Bioactive materials · 2025Review
- Nanomedicine Approaches for Intervertebral Disc Regeneration: From Bench to Bedside.Pharmaceutics · 2025Review
- Nano-Drug Delivery System Targeting the Oxidative Stress Microenvironment: A Prospective Strategy for Intervertebral Disc Degeneration Treatment.International journal of nanomedicine · 2025Review
- Reactive Oxygen Species Scavenging Capacity of Functional Fullerenes in Solution and in Macrophage Cells.ACS applied nano materials · 2024Article
- Progress in regulating inflammatory biomaterials for intervertebral disc regeneration.Bioactive materials · 2024Review
- Water-Soluble Fullerene Monoderivatives for Biomedical Applications.ChemMedChem · 2023Article
- Transient depletion of macrophages alters local inflammatory response at the site of disc herniation in a transgenic mouse model.Osteoarthritis and cartilage · 2023Article
- Multiple nano-drug delivery systems for intervertebral disc degeneration: Current status and future perspectives.Bioactive materials · 2023Review
- Formyl peptide receptors in bone research.Connective tissue research · 2023Review
- Precision medicine strategies for spinal degenerative diseases: Injectable biomaterials with in situ repair and regeneration.Materials today. Bio · 2022Review
- Molecule-to-Material-to-Bio Nanoarchitectonics with Biomedical Fullerene Nanoparticles.Materials (Basel, Switzerland) · 2022Review
- Amine Functionalized Trimetallic Nitride Endohedral Fullerenes: A Class of Nanoparticle to Tackle Low Back/Leg Pain.ACS applied bio materials · 2022Article
- Carbon Graphitization: Towards Greener Alternatives to Develop Nanomaterials for Targeted Drug Delivery.Biomedicines · 2022Review
- New Progress in Basic Research of Macrophages in the Pathogenesis and Treatment of Low Back Pain.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Intervertebral disc degeneration associated back pain is the most common cause of disability worldwide; however, no safe and effective treatments have been available. Here, we report a new functionalized nanofullerene conjugated with a peptide that binds specifically to a formyl peptide receptor-1 (FPR-1) expressed on activated macrophages. The new nanoparticle (aka FT-C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.